FinancialContent

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

46.09 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations ↗
Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss. 
Via Chartmill
News headline image
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Scholar Rock
Via Business Wire
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
News headline image
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks ↗
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten. 
Via Benzinga
News headline image
What to Expect from Scholar Rock Holding's Earnings ↗
 
Via Benzinga
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
3 Beaten-Down Stocks With Rebound Potential This Earnings Season ↗
Via MarketBeat
News headline image
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Alpha Buying: 3 Stocks With Sky-High Insider Confidence ↗
 
Via Benzinga
News headline image
Why Scholar Rock Stock Got Socked on Monday ↗
The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects. 
Via The Motley Fool
Topics Earnings
News headline image
Why Is Scholar Rock Stock Trading Lower On Monday? ↗
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial. 
Via Benzinga
News headline image
Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Scholar Rock Stock Raced 6% Higher Today ↗
A pundit at an influential U.S. bank is quite bullish on the company's future. 
Via The Motley Fool
News headline image
This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA... 
Via Benzinga
Topics Stocks
News headline image
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗
FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market. 
Via Benzinga
News headline image
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗
Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug. 
Via Investor's Business Daily
News headline image
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
From Scholar Rock
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >